Search Results
Glutaminase C-IN-1 10 mg | 99.82%
TargetMol
TPI-1 5 mg | 99.79%
TargetMol
TPI-1 50 mg | 99.79%
TargetMol
TPI-1 25 mg | 99.79%
TargetMol
TPI-1 10 mg | 99.79%
TargetMol
SR9009 5 mg | 99.80%
TargetMol

SR9009, a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice. The circadian pattern of expression of an array of metabolic genes […]
More Information Supplier PageSR9009 50 mg | 99.80%
TargetMol

SR9009, a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice. The circadian pattern of expression of an array of metabolic genes […]
More Information Supplier PageSR9009 25 mg | 99.80%
TargetMol

SR9009, a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice. The circadian pattern of expression of an array of metabolic genes […]
More Information Supplier PageSR9009 10 mg | 99.80%
TargetMol

SR9009, a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice. The circadian pattern of expression of an array of metabolic genes […]
More Information Supplier Page